Penumbral selection of patients for trials of acute stroke therapy
Authors:
- Geoffrey A DonnanGDGeoffrey A Donnan
- Jean-Claude BaronJBJean-Claude Baron
- Henry MaHMHenry Ma
- Stephen M DavisSDStephen M Davis
- 1 March 2009
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 8 (3) , 261-269
Abstract
No abstract availableKeywords
This publication has 70 references indexed in Scilit:
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeNew England Journal of Medicine, 2008
- StrokeThe Lancet, 2008
- National US Estimates of Recombinant Tissue Plasminogen Activator UseStroke, 2008
- Third International Stroke TrialInternational Journal of Stroke, 2006
- Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit?Cerebrovascular Diseases, 2005
- tPA use for Stroke in the Registry of the Canadian Stroke NetworkCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2005
- Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trialsThe Lancet, 2004
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Thresholds in cerebral ischemia - the ischemic penumbra.Stroke, 1981
- Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia.Stroke, 1977